Literature DB >> 16871281

Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E and E627E.

S Schnittger, U Bacher, W Kern, M Schröder, T Haferlach, C Schoch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16871281     DOI： 10.1038/sj.leu.2404325

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  25 in total

1.  Chasing down the triple-negative myeloproliferative neoplasms: Implications for molecular diagnostics.

Authors:  Stephen E Langabeer
Journal:  JAKSTAT       Date:  2016-11-14

2.  Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis.

Authors:  Susanne Schnittger; Ulrike Bacher; Claudia Haferlach; Dietrich Beelen; Peter Bojko; Dieter Bürkle; Robert Dengler; Andrea Distelrath; Michael Eckart; Robert Eckert; Stefan Fries; Jan Knoblich; Georg Köchling; Hans-Peter Laubenstein; Petro Petrides; Manfred Planker; Rudolf Pihusch; Rudolf Weide; Wolfgang Kern; Torsten Haferlach
Journal:  Haematologica       Date:  2008-11-23       Impact factor: 9.941

3.  High resolution melting analysis for JAK2 Exon 14 and Exon 12 mutations: a diagnostic tool for myeloproliferative neoplasms.

Authors:  Inmaculada Rapado; Silvia Grande; Enriqueta Albizua; Rosa Ayala; José-Angel Hernández; Miguel Gallardo; Florinda Gilsanz; Joaquin Martinez-Lopez
Journal:  J Mol Diagn       Date:  2009-03       Impact factor: 5.568

4.  A46, a benzothiophene-derived compound, suppresses Jak2-mediated pathologic cell growth.

Authors:  Anurima Majumder; Andrew T Magis; Sung O Park; Nicholas C Figueroa; Rebekah Baskin; Annet Kirabo; Robert W Allan; Zhizhuang Joe Zhao; Kirpal S Bisht; György M Keseru; Peter P Sayeski
Journal:  Exp Hematol       Date:  2011-10-20       Impact factor: 3.084

5.  High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome.

Authors:  M-T Krauth; C Eder; T Alpermann; U Bacher; N Nadarajah; W Kern; C Haferlach; T Haferlach; S Schnittger
Journal:  Leukemia       Date:  2014-01-09       Impact factor: 11.528

6.  High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms.

Authors:  Sabine Jeromin; Torsten Haferlach; Vera Grossmann; Tamara Alpermann; Andreas Kowarsch; Claudia Haferlach; Wolfgang Kern; Susanne Schnittger
Journal:  Haematologica       Date:  2012-08-28       Impact factor: 9.941

7.  Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases.

Authors:  Susanne Schnittger; Ulrike Bacher; Tamara Alpermann; Andreas Reiter; Madlen Ulke; Frank Dicker; Christiane Eder; Alexander Kohlmann; Vera Grossmann; Andreas Kowarsch; Wolfgang Kern; Claudia Haferlach; Torsten Haferlach
Journal:  Haematologica       Date:  2012-06-24       Impact factor: 9.941

8.  WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups.

Authors:  M-T Krauth; T Alpermann; U Bacher; C Eder; F Dicker; M Ulke; S Kuznia; N Nadarajah; W Kern; C Haferlach; T Haferlach; S Schnittger
Journal:  Leukemia       Date:  2014-08-11       Impact factor: 11.528

9.  Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses.

Authors:  Leila N Varghese; Daniela Ungureanu; Nicholas P D Liau; Samuel N Young; Artem Laktyushin; Henrik Hammaren; Isabelle S Lucet; Nicos A Nicola; Olli Silvennoinen; Jeffrey J Babon; James M Murphy
Journal:  Biochem J       Date:  2014-03-01       Impact factor: 3.857

10.  HSP90 is essential for Jak-STAT signaling in classical Hodgkin lymphoma cells.

Authors:  Nils Schoof; Frederike von Bonin; Lorenz Trümper; Dieter Kube
Journal:  Cell Commun Signal       Date:  2009-07-16       Impact factor: 5.712
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.